MD2B: Hematologic Malignancies

MD2B - Acute Leukemias
MD2B - Hodgkin's Disease
MD2B - Myeloproliferative Disorders
MD2B - Non-Hodgkin's Lymphoma

Bortezomib Beneficial in Graft-Versus-Host Disease Prophylaxis

Aug 9, 2012 - Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor reduced-intensity conditioning hematopoietic stem cell transplantation may benefit from a prophylactic, short-course, bortezomib-based regimen to reduce the incidence of graft-versus-host disease, according to research published online Aug. 6 in the Journal of Clinical Oncology.

OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More